Lupin and Zentiva Sign Pact to Commercialise Certolizumab

10 Jul 2025 CW Team

This strategic alliance aims to accelerate the availability of high-quality, cost-effective biosimilar Certolizumab Pegol to patients worldwide.

Lupin will be responsible for the development, manufacturing and supply of the product within the agreed territories. Zentiva will oversee commercialization activities outside USA and Canada, predominantly in Europe and CIS markets, where it will leverage its extensive European commercial infrastructure and regulatory expertise. Lupin will undertake commercialization in the remaining regions, including USA and Canada.

Both parties will invest in the development of the new biosimilar. Lupin will receive an initial payment of $10 million upon execution of the agreement and total development and regulatory milestone payments up to $50 million. The profits from the defined markets will be shared between the two companies.

Certolizumab Pegol is a recombinant, humanized antibody Fab' fragment, with specificity for human tumor necrosis factor alpha (TNFα), conjugated to an approximately 40kDa polyethylene glycol. It is indicated for the treatment of patients with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, non-radiographic axial spondyloarthritis, moderate-to-severe plaque psoriasis and Crohn’s disease.

“Our global development and commercialization partnership with Zentiva, with its pan- European focus, enables Lupin to commercialize this unique biosimilar in its core markets and through Zentiva in Europe,” said Fabrice Egros, President of Corporate Development, Lupin. “This partnership underscores our dedication to improving the quality of life for individuals living with chronic conditions and ensuring accessibility and affordability of transformative therapies worldwide."

Global Pharma major Lupin (Lupin) and Zentiva Group (Zentiva), a pan-European pharmaceutical company, have entered into a license and supply agreement for commercialisation of Lupin’s biosimilar Certolizumab Pegol, across multiple markets globally.This strategic alliance aims to accelerate the availability of high-quality, cost-effective biosimilar Certolizumab Pegol to patients worldwide.Lupin will be responsible for the development, manufacturing and supply of the product within the agreed territories. Zentiva will oversee commercialization activities outside USA and Canada, predominantly in Europe and CIS markets, where it will leverage its extensive European commercial infrastructure and regulatory expertise. Lupin will undertake commercialization in the remaining regions, including USA and Canada.Both parties will invest in the development of the new biosimilar. Lupin will receive an initial payment of $10 million upon execution of the agreement and total development and regulatory milestone payments up to $50 million. The profits from the defined markets will be shared between the two companies.Certolizumab Pegol is a recombinant, humanized antibody Fab' fragment, with specificity for human tumor necrosis factor alpha (TNFα), conjugated to an approximately 40kDa polyethylene glycol. It is indicated for the treatment of patients with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, non-radiographic axial spondyloarthritis, moderate-to-severe plaque psoriasis and Crohn’s disease.“Our global development and commercialization partnership with Zentiva, with its pan- European focus, enables Lupin to commercialize this unique biosimilar in its core markets and through Zentiva in Europe,” said Fabrice Egros, President of Corporate Development, Lupin. “This partnership underscores our dedication to improving the quality of life for individuals living with chronic conditions and ensuring accessibility and affordability of transformative therapies worldwide.

Infrastructure Transport

12 Jan 2026

Dhalbhumgarh Airport Faces 150-km Rule Hurdle

The issue has resurfaced following a recent statement by Union Civil Aviation Minister Ram Mohan Naidu, who said that under existing aviation policy, a new greenfield airport is generally not permitted within an aerial distance of 150 kilometres of an operational civilian airport. He added, however, that if a formal proposal is submitted, its impact on the existing airport can be examined and relaxations may be considered on a case-by-case basis. While the clarification has revived some hope for Dhalbhumgarh, it has also underlined the scale of the technical challenge facing the project. Unde..

Infrastructure Transport

12 Jan 2026

Stakeholders Seek Parallel Ops For Vizag Airports

With road and metro rail links to Bhogapuram still several years away, stakeholders in north Andhra Pradesh have renewed demands to continue civil operations at INS Dega even after the commissioning of Bhogapuram International Airport. The new airport is expected to begin commercial operations from June. Officials said close to 80 per cent of the airport infrastructure at Bhogapuram, including the terminal building and internal approach roads, has already been completed. However, inadequate external connectivity remains a key concern. Making a case for parallel operations, Andhra Pradesh Air ..

Infrastructure Transport

12 Jan 2026

Govt To Roll Out V2V Tech To Cut Road Crashes

In an effort to curb road accidents, particularly in low-visibility conditions such as dense fog, the government is set to roll out vehicle-to-vehicle (V2V) communication technology that will allow cars to exchange real-time data and alert drivers to potential dangers. The announcement was made by Union Road Transport and Highways Minister Nitin Gadkari after the 43rd meeting of the Transport Development Council. The technology involves installing an on-board unit (OBU) in vehicles, enabling wireless data exchange between nearby cars. This will allow vehicles to share information such as spee..